The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine
Launched by NATIONAL TAIWAN UNIVERSITY CLINICAL TRIAL CENTER · Aug 17, 2025
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a long-acting injection of two medicines, cabotegravir and rilpivirine, affects the quality of life and virus control in people living with HIV/AIDS. Normally, people with HIV take daily pills to keep the virus under control, but missing doses can cause problems like drug resistance and treatment failure. This study looks at whether switching to a monthly injection can help people avoid forgetting their medicine, reduce worries about storing pills, and improve their overall well-being by decreasing side effects like tiredness, anxiety, and sleep problems.
Adults aged 18 and older who have been diagnosed with HIV and have already started treatment with these long-acting injections may be eligible to join. Participants will be asked to share their experiences through questionnaires about how they feel, how the treatment affects their daily life and activity, and how satisfied they are with the injections. The goal is to see if this new way of taking medicine can make life easier and better for people living with HIV.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire
- Exclusion Criteria:
- • Not clinical diagnosis of HIV infection Do not accept questionnaires
About National Taiwan University Clinical Trial Center
The National Taiwan University Clinical Trial Center is a leading institution dedicated to advancing medical research through the design, implementation, and management of clinical trials. Affiliated with National Taiwan University, the center leverages its academic expertise and state-of-the-art facilities to facilitate innovative studies across various therapeutic areas. Committed to upholding the highest ethical standards and regulatory compliance, the center collaborates with healthcare professionals, researchers, and industry partners to enhance patient care and contribute to the global medical community. Through its rigorous approach, the center aims to accelerate the development of new treatments and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported